$REPL
Replimune Group, Inc.

2023 Q4 Form 10-Q Financial Statement

#000173795323000017 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.69M $14.73M $12.75M
YoY Change 20.44% 15.57% 36.38%
% of Gross Profit
Research & Development $42.85M $49.10M $28.83M
YoY Change 41.59% 70.29% 44.88%
% of Gross Profit
Depreciation & Amortization $700.0K $700.0K $617.0K
YoY Change 2.64% 13.45% 15.98%
% of Gross Profit
Operating Expenses $56.54M $63.83M $41.58M
YoY Change 35.82% 53.52% 42.17%
Operating Profit -$56.54M -$63.83M -$41.58M
YoY Change 35.82% 53.52% 42.17%
Interest Expense $4.134M $4.550M $562.0K
YoY Change 248.57% 709.61% -217.82%
% of Operating Profit
Other Income/Expense, Net $5.893M $3.586M -$1.523M
YoY Change 203.76% -335.46% 1310.19%
Pretax Income -$50.65M -$60.25M -$43.10M
YoY Change 27.61% 39.77% 46.83%
Income Tax $500.0K -$200.0K $0.00
% Of Pretax Income
Net Earnings -$51.10M -$60.00M -$43.10M
YoY Change 28.72% 39.21% 46.82%
Net Earnings / Revenue
Basic Earnings Per Share -$0.77 -$0.90 -$0.79
Diluted Earnings Per Share -$0.77 -$0.90 -$0.79
COMMON SHARES
Basic Shares Outstanding 59.06M shares 59.00M shares 49.31M shares
Diluted Shares Outstanding 66.65M shares 66.58M shares 54.77M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $466.4M $496.8M $371.8M
YoY Change -24.34% 33.61% -14.68%
Cash & Equivalents $97.67M $76.00M $88.93M
Short-Term Investments $368.7M $420.8M $282.9M
Other Short-Term Assets $8.518M $8.500M $4.981M
YoY Change 52.35% 70.65% -13.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $479.2M $508.2M $379.4M
YoY Change -23.21% 33.95% -14.63%
LONG-TERM ASSETS
Property, Plant & Equipment $9.473M $8.445M $7.910M
YoY Change 23.36% 6.76% 10.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.636M $1.600M $1.636M
YoY Change 0.0% -2.2% 0.0%
Total Long-Term Assets $53.77M $54.22M $56.71M
YoY Change -1.51% -4.38% -4.02%
TOTAL ASSETS
Total Short-Term Assets $479.2M $508.2M $379.4M
Total Long-Term Assets $53.77M $54.22M $56.71M
Total Assets $532.9M $562.4M $436.1M
YoY Change -21.46% 28.96% -13.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.903M $4.365M $3.996M
YoY Change 6.99% 9.23% 26.7%
Accrued Expenses $28.49M $28.90M $14.43M
YoY Change 49.54% 100.35% 43.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.698M $2.700M $2.600M
YoY Change 3.02% 3.85% 3.01%
Total Short-Term Liabilities $38.65M $39.83M $23.54M
YoY Change 46.05% 69.23% 41.48%
LONG-TERM LIABILITIES
Long-Term Debt $68.00M $52.90M $24.21M
YoY Change 29.57% 118.54% -1.58%
Other Long-Term Liabilities $793.0K $472.0K $4.280M
YoY Change -81.41% -88.97% -11.24%
Total Long-Term Liabilities $793.0K $472.0K $28.49M
YoY Change -98.6% -98.34% -3.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $38.65M $39.83M $23.54M
Total Long-Term Liabilities $793.0K $472.0K $28.49M
Total Liabilities $111.4M $97.23M $52.02M
YoY Change 33.88% 86.89% 12.97%
SHAREHOLDERS EQUITY
Retained Earnings -$646.2M -$595.1M -$396.6M
YoY Change 48.14% 50.05% 58.75%
Common Stock $61.00K $59.00K $50.00K
YoY Change 7.02% 18.0% 6.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $421.5M $465.2M $384.1M
YoY Change
Total Liabilities & Shareholders Equity $532.9M $562.4M $436.1M
YoY Change -21.46% 28.96% -13.38%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$51.10M -$60.00M -$43.10M
YoY Change 28.72% 39.21% 46.82%
Depreciation, Depletion And Amortization $700.0K $700.0K $617.0K
YoY Change 2.64% 13.45% 15.98%
Cash From Operating Activities -$47.12M -$43.59M -$33.21M
YoY Change 64.82% 31.26% 44.64%
INVESTING ACTIVITIES
Capital Expenditures $1.722M $1.750M -$396.0K
YoY Change 210.27% -541.92% -7.48%
Acquisitions
YoY Change
Other Investing Activities $55.67M $14.44M $432.0K
YoY Change -144.7% 3242.59% -104.07%
Cash From Investing Activities $53.96M $12.68M $36.00K
YoY Change -143.13% 35122.22% -100.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.87M 430.0K 7.423M
YoY Change -94.52% -94.21% 545.48%
NET CHANGE
Cash From Operating Activities -47.12M -43.59M -33.21M
Cash From Investing Activities 53.96M 12.68M 36.00K
Cash From Financing Activities 14.87M 430.0K 7.423M
Net Change In Cash 21.71M -30.48M -25.75M
YoY Change -81.56% 18.36% -21.64%
FREE CASH FLOW
Cash From Operating Activities -$47.12M -$43.59M -$33.21M
Capital Expenditures $1.722M $1.750M -$396.0K
Free Cash Flow -$48.84M -$45.34M -$32.81M
YoY Change 67.59% 38.17% 45.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5208000 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
39665000 usd
CY2023Q1 us-gaap Assets
Assets
646591000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4389000 usd
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
23965000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
29161000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
28648000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
472000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
91299000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56676313 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
57000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1034994000 usd
CY2023Q1 repl Research And Development Incentives Receivable Noncurrent
ResearchAndDevelopmentIncentivesReceivableNoncurrent
0 usd
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1636000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5364000 usd
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24704000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1118000 usd
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2639000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
33825000 usd
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59059343 shares
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-485488000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5729000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
555292000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
646591000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58312000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24143000 usd
us-gaap Operating Expenses
OperatingExpenses
82455000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-82455000 usd
repl Research And Development Incentives Income
ResearchAndDevelopmentIncentivesIncome
1425000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1455000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1102000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4678000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-85355000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85355000 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66582280 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66582280 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54492395 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54492395 shares
us-gaap Net Income Loss
NetIncomeLoss
-85355000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4067000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
0 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81451000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
555292000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1305000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-458000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1209000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8846000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-49555000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
514029000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1308000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
214000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
550000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9114000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-60044000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
465172000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
411229000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
31037000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1562000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7194000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-42253000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
410262000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6401000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2330000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
81000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1108000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
513000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
0 usd
repl Unrealized Foreign Currency Transaction Loss Before Tax
UnrealizedForeignCurrencyTransactionLossBeforeTax
-37000 usd
repl Unrealized Foreign Currency Transaction Loss Before Tax
UnrealizedForeignCurrencyTransactionLossBeforeTax
0 usd
repl Proceeds From Issuance Of Common Stock Through Atm Sales Net
ProceedsFromIssuanceOfCommonStockThroughATMSalesNet
0 usd
repl Proceeds From Issuance Of Common Stock Through Atm Sales Net
ProceedsFromIssuanceOfCommonStockThroughATMSalesNet
37438000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
217000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
163000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1760000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2670000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1543000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
39945000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4351000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-70594000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17018000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148226000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
107584000 usd
us-gaap Interest Paid Net
InterestPaidNet
1343000 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
300000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
138000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
96000 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
300000 usd
us-gaap Nature Of Operations
NatureOfOperations
Nature of the business<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Replimune Group, Inc. (the “Company”) is a clinical-stage biotechnology company with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. The Company's proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Replimune Group, Inc., whose predecessor was founded in 2015, is the parent company of its wholly owned, direct and indirect subsidiaries: Replimune Limited (“Replimune UK”); Replimune, Inc. (“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, third-party intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since its inception, including net losses of $60.0 million and $43.1 million for the three months ended September 30, 2023 and 2022, respectively, and net losses of $109.6 million and $85.4 million for the six months ended September 30, 2023 and 2022, respectively. In addition, as of September 30, 2023, the Company had an accumulated deficit of $595.1 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of these consolidated financial statements.</span></div>
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-60000000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-43100000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-595100000 usd
us-gaap Use Of Estimates
UseOfEstimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16962000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14721000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8517000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7242000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8445000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7479000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
700000 usd
us-gaap Depreciation
Depreciation
1300000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
600000 usd
us-gaap Depreciation
Depreciation
1200000 usd
CY2022Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
340000 shares
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6700000 usd
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6700000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
300000 usd
CY2023Q3 repl Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
19945000 usd
CY2023Q1 repl Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
11261000 usd
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
7128000 usd
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9909000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
687000 usd
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
540000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3891000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2994000 usd
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
31651000 usd
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24704000 usd
CY2023Q3 repl Long Term Debt Instrument Covenant Requirement Unrestricted Cash Percentage Of Obligations
LongTermDebtInstrumentCovenantRequirementUnrestrictedCashPercentageOfObligations
0.35
CY2022Q4 repl Long Term Debt End Of Term Charge
LongTermDebtEndOfTermCharge
1500000 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
340000 shares
CY2022Q4 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
6810658000 shares
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
242600000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9114000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6992000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17961000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14186000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9114000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6992000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17961000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14186000 usd
CY2017Q3 repl Conversion Of Stock Ratio
ConversionOfStockRatio
1
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
125000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
82500 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
125000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2064526 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.08
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
163356 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
200611 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
24.73
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9155387 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M10D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
27858000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5400346 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
26556000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
9155387 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
17.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y9M10D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
27858000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.19
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.20
repl Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
1300000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-60044000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-43102000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-109599000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85355000 usd
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66582280 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66582280 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54770291 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54770291 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66475577 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66475577 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54492395 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54492395 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.57
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7561583 shares
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1214000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1102000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
511000 usd
us-gaap Lease Cost
LeaseCost
2827000 usd
CY2023Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
542000 usd
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
550000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1086000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1102000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
568000 usd
CY2023Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
1335000 usd
CY2023Q3 repl Operating And Finance Lease Liability Payments Remainder Of Fiscal Year
OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
1903000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1143000 usd
CY2023Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
2718000 usd
CY2023Q3 repl Operating And Finance Lease Liability Payments Due Next Twelve Months
OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths
3861000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1152000 usd
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
2799000 usd
CY2023Q3 repl Operating And Finance Lease Liability Payments Due Year Two
OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo
3951000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1120000 usd
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
2883000 usd
CY2023Q3 repl Operating And Finance Lease Liability Payments Due Year Three
OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree
4003000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1071000 usd
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
2969000 usd
CY2023Q3 repl Operating Finance Lease Liability Payments Due Year Four
OperatingFinanceLeaseLiabilityPaymentsDueYearFour
4040000 usd
CY2023Q3 repl Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
1891000 usd
CY2023Q3 repl Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
35054000 usd
CY2023Q3 repl Operating And Finance Lease Liability Payments Due After Year Four
OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour
36945000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6945000 usd
CY2023Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
47758000 usd
CY2023Q3 repl Operating And Finance Lease Liability Payments Due
OperatingAndFinanceLeaseLiabilityPaymentsDue
54703000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1755000 usd
CY2023Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
21371000 usd
CY2023Q3 repl Operating And Finance Lease Liability Undiscounted Excess Amount
OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount
23126000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5190000 usd
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
26387000 usd
CY2023Q3 repl Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
31577000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4882000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5208000 usd
CY2023Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
38451000 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
39665000 usd
CY2023Q3 repl Lease Right Of Use Asset
LeaseRightOfUseAsset
43333000 usd
CY2023Q1 repl Lease Right Of Use Asset
LeaseRightOfUseAsset
44873000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1138000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1118000 usd
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2678000 usd
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2639000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4052000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4389000 usd
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
23709000 usd
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
23965000 usd
CY2023Q3 repl Lease Liability
LeaseLiability
31577000 usd
CY2023Q1 repl Lease Liability
LeaseLiability
32111000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
528000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
466000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1086000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1102000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
217000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
163000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y1M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P15Y9M18D
CY2022Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P16Y9M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.102
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.083
CY2022Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.083
CY2023Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
1000000 usd
CY2023Q1 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
1000000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
repl Number Of Operating Geographic Regions
NumberOfOperatingGeographicRegions
2 region
CY2023Q3 us-gaap Noncurrent Assets
NoncurrentAssets
8445000 usd
CY2023Q1 us-gaap Noncurrent Assets
NoncurrentAssets
7479000 usd

Files In Submission

Name View Source Status
repl-20230930_lab.xml Edgar Link unprocessable
repl-20230930_cal.xml Edgar Link unprocessable
0001737953-23-000017-index-headers.html Edgar Link pending
0001737953-23-000017-index.html Edgar Link pending
0001737953-23-000017.txt Edgar Link pending
0001737953-23-000017-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
repl-20230930.htm Edgar Link pending
repl-20230930.xsd Edgar Link pending
repl-93023x10qxex311.htm Edgar Link pending
repl-93023x10qxex312.htm Edgar Link pending
repl-93023x10qxex321.htm Edgar Link pending
repl-93023x10qxex322.htm Edgar Link pending
repl-emilyhillcfoemploymen.htm Edgar Link pending
replimune-espositoemployme.htm Edgar Link pending
replimunegroupinc-induceme.htm Edgar Link pending
replimunegroupinc-restrict.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
repl-20230930_def.xml Edgar Link unprocessable
repl-20230930_pre.xml Edgar Link unprocessable
repl-20230930_htm.xml Edgar Link completed